Dr. Belani on PD-1 Inhibitors for Non-Small Cell Lung Cancer

Chandra P. Belani, MD
Published: Wednesday, Jan 28, 2015



Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the benefits of immunotherapy for lung cancer.

Checkpoint inhibitors targeting PD-1 and PD-L1 have started to show beneficial effects in patients with non-small cell lung cancer, says Belani. The drugs that target PD-1 and PDL-1 lead to increases in the patients. own tumor immunity. Not all patients respond, but there may be a biomarker for treatment to determine when to utilize these therapies.


Chandra P. Belani, MD, deputy director, Penn State Hershey Cancer Institute, Miriam Beckner Distinguished Professor of Medicine, Penn State Hershey College of Medicine, discusses the benefits of immunotherapy for lung cancer.

Checkpoint inhibitors targeting PD-1 and PD-L1 have started to show beneficial effects in patients with non-small cell lung cancer, says Belani. The drugs that target PD-1 and PDL-1 lead to increases in the patients. own tumor immunity. Not all patients respond, but there may be a biomarker for treatment to determine when to utilize these therapies.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x